![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 02 June 2021
Sec. Pharmacology of Anti-Cancer Drugs
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.687841
This article is a correction to:
RETRACTED: Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin
A Corrigendum on
Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin
By Li B, Zhao X, Zhang L and Cheng W (2021). Front. Oncol. 10:588533. doi: 10.3389/fonc.2020.588533
In the original article, there was a mistake in Figure 7C as published. The images in Figure 7C are incorrectly assembled due to incorrect naming of the image files. The corrected Figure 7 appears below.
Figure 7 BC cells complemented with AKT-1-si or AKT-1-oe regulated to Emodin. (A) The expression of AKT1 after treatment with AKT1-siRNA or AKT1 overexpression. (B) CCK-8 assay shows the BC cells complemented with AKT1-siRNA or AKT1 over-expression. (C) DNA damage assays shows that the BC cells complemented with AKT1-siRNA promote Emodin compared with cells treated with AKT1-siRNA or Emodin alone. (D) DNA damage assays shows that the BC cells complemented with AKT1 over-expression resists Emodin compared with cells treated with AKT1-overexpression or Emodin alone. The analysis was conducted using the Student’s t-test. p > 0.05, **p < 0.01, *p < 0.05.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: AKT1, DNA repair, bioinformatics, breast cancer, emodin
Citation: Li B, Zhao X, Zhang L and Cheng W (2021) Corrigendum: Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin. Front. Oncol. 11:687841. doi: 10.3389/fonc.2021.687841
Received: 30 March 2021; Accepted: 19 April 2021;
Published: 02 June 2021.
Copyright © 2021 Li, Zhao, Zhang and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wen Cheng, Y2hlbmd3ZW42OUB5YWhvby5jb20=
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.